Stay updated with breaking news from விட் மயோ. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Published: Jul 02, 2021 By Alex Keown OcuTerra Therapeutics – David J. Tanzer was named Chief Medical Officer and Executive Vice President, Clinical and Medical Affairs for Boston-based OcuTerra. Prior to joining OcuTerra, Tanzer served as Global Executive Medical Director in the Novartis ophthalmology franchise. Before that, he served as the CMO at Abbott Medical Optics. He also led the Navy Refractive Surgery Program in San Diego, participating as principal or co-investigator in over 50 clinical studies. Delix Therapeutics – David E. Olson, co-founder and Chief Scientific Officer of Delix Therapeutics, was an Innovator of the Year award winner at UC Davis. Olson is an assistant professor in the Department of Chemistry and Department of Biochemistry and Molecular Medicine at UC Davis. He was named an Innovator of the Year for his groundbreaking work with non-hallucinatory psychedelics that have the potential to make “measurable societal impact.” Ol ....
SVB Leerink Hires Whit Mayo to Lead Healthcare Providers & Managed Care Equity Research prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.
Getty Images Stocks with smaller market values are outperforming by a wide margin so far this year, and strategists and analysts alike say small caps should continue to lead the way as the economic recovery gains steam. The U.S. economy is currently trending toward high-single digit GDP growth in 2021 as COVID-19 vaccine distribution expands and we gradually emerge from the pandemic, says Lule Demmissie, president of Ally Invest. That environment favors small-cap names, which tend to have a more domestic focus than larger multinational firms. Small caps tend to outperform in the early parts of the economic cycle, so it should come as no surprise that they are clobbering stocks with larger market values these days. ....
In his latest research note, analyst Whit Mayo confirms his positive recommendation. The broker UBS is keeping its Buy rating. The target price is lowered from EUR 94 to EUR 72. | February 21, 2021 ....